KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Amortization - Intangibles (2017 - 2025)

Historic Amortization - Intangibles for Sarepta Therapeutics (SRPT) over the last 9 years, with Q2 2025 value amounting to $667000.0.

  • Sarepta Therapeutics' Amortization - Intangibles rose 1098.17% to $667000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $2.5 million, marking a year-over-year increase of 278.7%. This contributed to the annual value of $2.4 million for FY2024, which is 5426.56% up from last year.
  • Sarepta Therapeutics' Amortization - Intangibles amounted to $667000.0 in Q2 2025, which was up 1098.17% from $601000.0 recorded in Q4 2024.
  • Sarepta Therapeutics' Amortization - Intangibles' 5-year high stood at $763000.0 during Q4 2023, with a 5-year trough of $170000.0 in Q1 2021.
  • In the last 5 years, Sarepta Therapeutics' Amortization - Intangibles had a median value of $179000.0 in 2021 and averaged $355941.2.
  • As far as peak fluctuations go, Sarepta Therapeutics' Amortization - Intangibles skyrocketed by 32625.7% in 2023, and later crashed by 2123.2% in 2024.
  • Sarepta Therapeutics' Amortization - Intangibles (Quarter) stood at $179000.0 in 2021, then changed by 0.0% to $179000.0 in 2022, then soared by 326.26% to $763000.0 in 2023, then decreased by 21.23% to $601000.0 in 2024, then increased by 10.98% to $667000.0 in 2025.
  • Its last three reported values are $667000.0 in Q2 2025, $601000.0 for Q4 2024, and $602000.0 during Q3 2024.